This sensor demonstrates improved sensitivity and biocompatibility in cancer detection, suggesting promising applications.
Early detection of cancer remains a key challenge because current SPR-PCF sensors lack both sensitivity and robust light–analyte interaction. To overcome these limitations, this study proposed and validated an SPR biosensor utilizing MXene-functionalized PCF. By introducing a composite structure of MXene nanomaterials and Au, the detection performance of the sensor was significantly improved. The sensor adopts a circular air hole arrangement and double-groove morphology design and leverages MXene’s high conductivity and gold’s chemical stability to simultaneously enhance plasmonic coupling and biocompatibility. Through FEM-based structural optimization of the air hole diameter, Au layer thickness, and groove shape, the sensor exhibited outstanding refractive-index detection performance with a wavelength sensitivity of 11,072 nm/RIU, an impressive quality factor reaching 201.3 RIU−1, and a resolution as fine as 9.03 × 10−6 RIU. The simulation results demonstrated the capability of the sensor to discriminate six distinct cancer-cell types (cervical cancer HeLa, leukemia Jurkat, pheochromocytoma PC-12, triple-negative breast cancer MDA-MB-231, and breast cancer MCF-7) with high sensitivity and verify its ability to detect pan-cancer species. This study demonstrates an innovative approach for constructing a high-performance SPR sensing platform that has important application potential in the context of the early detection of multiple cancers.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: